Biocon - Steady Q2; Generics Business Remains Under Pressure: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Biocon Ltd. has reported revenue in line with our estimates while profit beat estimates on the back of better margins and higher other income.
Biosimilar segment remained steady QoQ; however, generics was impacted due to continuous pricing pressure in the U.S.
Consolidated revenue grew 5.5% YoY to Rs 18.4 billion (our estimate: Rs 18.0 billion), adjusted Ebitda margin improved 180 basis points YoY (up 210 bps QoQ) to 24.2% (our estimate: 23.0%) and adjusted profit after tax grew 13.8% YoY to Rs 1.9 billion (our estimate: Rs 1.1 billion).
Biocon Biologics recently entered into an agreement with Serum Institute for vaccines by offering 15% stake which is valuation neutral, in our view.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.